申请人:EnVivo Pharmaceuticals, Inc.
公开号:US20140187786A1
公开(公告)日:2014-07-03
Compounds that are 1,3,4-trisubstituted benzenes which modulate (e.g., inhibit) the activity of γ-secretase. The compounds are expected to reduce the level of Aβ42 in patients and be useful in the treatment of diseases (e.g., Alzheimer's disease) characterized by elevated levels of Aβ42 and/or the formation of Aβ plaques.
这句话的意思是:1,3,4-三取代苯类化合物可以调节(例如抑制)γ-分泌酶的活性。这些化合物预计可以降低患者体内的Aβ42水平,并且在治疗由Aβ42水平升高和/或Aβ斑块形成所特征的疾病(例如阿尔茨海默病)中有用。